PT - JOURNAL ARTICLE AU - Skarda, Jozef AU - Fridman, Eduard AU - Plevova, Pavlina AU - Hajduch, Marian AU - Radova, Lenka AU - Ofek, Efrat AU - Kopolovic, Jury AU - Kolek, Vitezslav AU - Kolar, Zdenek TI - PROGNOSTIC VALUE OF hMLH1 AND hMSH2 IMMUNOHISTOCHEMICAL EXPRESSION IN NON-SMALL CELL LUNG CANCER. A TISSUE MICROARRAY STUDY DP - 2006 Dec 1 TA - Biomedical papers PG - 255--259 VI - 150 IP - 2 AID - 10.5507/bp.2006.037 IS - 12138118 AB - Background: hMLH1 and hMSH2 genes are both known to play a role in DNA mismatch repair. Nonetheless, the clinical significance of hMLH1 and hMSH2 protein expression in lung cancers remains unclear. Aim: The aim of this study was to investigate the immunohistochemical expression of hMLH1 and hMSH2 proteins in tumor specimens from 179 non-small cell lung cancer (NSCLC) patients using a tissue microarray technique and to correlate these results with other clinicopathological variables, including the disease specific and overall survivals. Method: hMLH1 and hMSH2 protein expression was evaluated by immunohistochemistry using monoclonal antibodies G168-728 for hMLH1 and FE11 for hMSH2 protein expression analysis. The Pearson χ<sup>2</sup> test was used to compare the hMLH1 and hMSH2 alterations among the cases and between various clinical and laboratory variables. P &lt; or = 0.05 was considered statistically significant. Results: Alteration of hMLH1 and hMSH2 protein expression was observed in 10 % of patients. No significant correlation was found between the protein expression and patient age, smoking status, tumor histology or disease stage and disease free and overall survival. Conclusions: Alterations in the expression of hMLH1 and hMSH2 proteins did not have any prognostic value in stage III. NSCLC patients.